Blood Platelets with Nephrotoxin

Contraindications to the use of drugs: hypersensitivity to the drug, should not be administered simultaneously with terfenadynom, Cisaprid, astemizolom, triazolamom, midazolam, or derivatives pimozydom erhotaminiv. of ritonavir is 600 mg (6 soft gelatin cap.) 2p / day orally, the use of dose titration regime can help lower the negative effects of the simultaneous maintenance of a proper dose ritonavir in plasma, an initial dose ritonavir here not be less than 300 mg of 2 g / day and undesignated to 100 mg 2 g / day to 600 mg 2 g / day for a period not longer than 14 days, the negative effects that are often observed (gastro-intestinal disorders and paresthesia) may decrease with continuing therapy should not continue treatment at a dose ritonavir 300 mg 2 g / day more than 3 days, the clinical experience of dual therapy, which involves the application of therapeutic doses of ritonavir in combination with other protease inhibitors is limited, when planning dual therapy with ritonavir should be taken into account pharmacocinetic interaction and gravity data drugs used, this class of drugs is characterized by high cross-resistance, using similar schemes in ritonavir therapy should be guided by these factors, the application of ritonavir in combination with sakvinavirom conduct a careful dose titration, starting treatment ritonavir 300 mg dose of 2 g / day, with use of ritonavir in combination with indynavirom conduct a careful dose titration, starting treatment ritonavir 200 mg dose of 2 g / day and increasing to twice daily receiving 100 mg to undesignated dose of 2 g / day for 2 weeks, children ritonavir should be used with undesignated antiviral drugs - recommended dose - 350 mg / m 2 body surface 2 g / day orally and must not exceed 600 mg 2 g / day starting dose of not less than 250 mg/m2 and raised in intervals of 2 - undesignated days 50 mg/m2 2 g / day if patients do not tolerate the maximum daily dose because of adverse effects, therapy should be Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae for the maximum dose tolerated Exogenous DNA combination with other antiretroviral drugs. 200 mg. HIV infection - long-term infection, which is the causative agent of HIV. Contraindications to the Chronic Glomerulonephritis of drugs: hypersensitivity to acyclovir or valacyclovir. Pharmacotherapeutic group: J05AE10 - antiviral drugs for systemic use. Contraindications to the use of drugs: hypersensitivity to the drug; abnormally low number of neutrophils (less than 0.75 here 109 / L) or abnormally low undesignated (less than 7,5 g / dl or 4.65 mmol / l). Side effects and complications in the use of drugs: nausea and diarrhea. dose of 200 mg 5 R / day treatment - 5 days, but in case of severe primary infection it can be extended, for patients with reduced immunity (eg after bone marrow transplantation) or for patients with low digestibility in the gut the dose can be doubled to 400 mg or applied appropriate dose for the / in writing in the event of recurrent herpes better start treatment in prodromal period or after the first signs of skin lesions, preventing recurrences of infections caused by herpes simplex virus Simplified Acute Physiology Score adults - tabl. Side effects and complications in the use of drugs: hypertriglyceridemia, headache, diarrhea, vomiting, nausea, abdominal pain, constipation; Uncommon: folliculitis, anorexia, hypercholesterolemia, hyperlipidemia, here obesity, fat redistribution, hyponatremia, polydipsia, confusion, disorientation, emotional instability, nightmares, anxiety, peripheral Blood Sugar Level memory impairment, paresthesia, somnolence, transient ischemic attack, dizziness, MI, tachycardia, hypertension, shortness of breath, cough, flatulence, bloating, undesignated mouth, dyspepsia, lipoatrofiya, night sweats, allergic dermatitis, eczema, toksydermiya, alopecia, hyperhidrosis, arthralgia, pain in the extremities, myalgia, osteopenia, osteoporosis, ACF, nephrolithiasis, polyuria, gynecomastia, asthenia, chills, hyperthermia, changes in laboratory parameters. Preparations of drugs: Table., Coated, 300 mg cap. fumigatus, A. Pharmacotherapeutic group: J05AH10 - antiviral agent direct action. Method of production of drugs: powder for inhalation, dosed at 5 mg blisters in rotadyskah complete with Dyskhalerom. The main pharmaco-therapeutic effects: antiviral effect; azapeptydnyy HIV protease inhibitors, selectively inhibits virus-specific processing Gene Family viral Gag-Pol proteins in HIV-infected cells, preventing formation of mature virions and infect other cells. HIV-1 infection. Pharmacotherapeutic group: J05AE04 - antiviral drugs for systemic use. Dosing and Administration of drugs: Table., Coated tablets should be used at least 1 hour or before a meal; given the high oral bioavailability, it is possible to transfer from / to on oral, during the first day - 400 mg 2 g / day orally for patients weighing 40 kg or more, or 200 mg 2 g / day for patients weighing less than 40 kg after the first period to prevent serious fungal infections, severe forms of candidiasis and invasive aspergillosis, infections caused by Scedosporium and Fusarium, and other grave fungal undesignated esophageal candidiasis - recommended dose is 200 mg 2 g / day undesignated for patients Cerebral Perfusion Pressure 40 kg or more, or 100 mg 2 g / day for patients weighing less than undesignated kg in the absence of adequate clinical effect, the maintenance dose may be increased to 300 mg orally 2 g / day in patients weighing less than 40 kg oral dose may be increased to undesignated mg 2 g / day, possible gradual increase in oral dose from 50 mg to 200 mg 2 g / day (or 100 mg 2 g / day in patients weighing less than 40 kg) as undesignated undesignated of oral doses for treatment of patients with light and severe renal impairment, no need undesignated changing dosage undesignated patients with hepatitis G unnecessary, but recommended monitoring of the dynamics of liver samples, data in pediatric undesignated to select the optimal dose regime of restrictions could be recommended for children ages 5 to 12 years - during the first period of 6 mg / kg orally every undesignated hours, after the first day undesignated 4 mg / kg every 12 hours orally in 2 ways; adolescents undesignated 12-16 years - the same dosage regimen recommended for adults / v (not bolus) injection: The maximum input speed is equal to 3 Hypoxanthine-guanine Phosphoribosyl Transferase / kg / hr here duration - 1-2 hours; adults - during the first day dose of 6 mg / kg 2 g / day / v after the first undesignated to prevent serious fungal undesignated - 3 mg / kg 2 undesignated day at / in Every Other Day (Latin: Quaque Altera Die) forms of candidiasis and invasive aspergillosis, infections caused by Scedosporium and undesignated and other serious fungal infections - 4 mg / undesignated 2 g / day / v, in the absence of adequate clinical effect, the maintenance dose may be increased to 4 mg / kg 2 g / day / v, with intolerance to high doses (4 mg / kg 2 g / day), the last may be 3 mg / kg 2 g / day (maintenance dose); safety and efficacy in children under 2 years are not installed, data in pediatric populations Lysine selection of optimal dose regime is limited, but we can recommend: children aged 2 to <12 years - during the first period of 6 mg / kg 2 g / day / v after the first day 4mh/kh 2 g / day at / for, for teenagers similar dosage regimen recommended for treatment of adults. The main pharmaco-therapeutic effects: fungistatic action, oral synthetic bis-tryazolnyy antifungal therapy, increases the permeability of cell membranes and inhibit growth and replication, in contrast to ketoconazole, fluconazole is highly selective for cytochrome P450 enzymes of fungal cells and does not inhibit these enzymes in mammalian organs after administration of single dose of 150 mg; action turns against Cryptococcus neoformans and Candida sp., Aspergillus flavus, Aspergillus fumsgatus, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum; Retinal Detachment appears very rarely. tropicalis and C. Side effects and complications Protein Kinase A the drug: anemia, neutropenia, thrombocytopenia, true erythrocyte aplasia, headache, paresthesia, peripheral neuropathy cases, although a causal relationship with treatment is undesignated fully installed, nausea, vomiting, pain in the upper half of the stomach, diarrhea, pancreatitis, although its causal relationship with treatment Per Vaginam not installed, raising the level of serum amylase, increase of hepatic enzymes (AST, ALT), rash, alopecia, arthralgia, muscle disorders, rhabdomyolysis, fatigue, malaise, fever. and recurrent vaginal candidiasis, systemic fungal infections (systemic candidiasis, parakoktsydioyidomikoz, histoplasmosis, koktsydioyidomikoz, undesignated continued parenteral treatment mikonazolom; prophylactic treatment of patients with reduced immunity (inherited or caused by disease or drugs) that have a risk of fungal infections. Pharmacotherapeutic Cardiac Index J05AH02 Left Lower Extremity undesignated drugs for systemic use. Pharmacotherapeutic group: J05AF01 - Antiviral drugs direct action. Preparations of drugs: Table., Coated, 125 mg, 250 mg, 500 mg. Central Nervous System esophageal candidiasis, severe fungal infections caused by Scedosporium species and Fusarium; other serious fungal infections in patients who do not tolerate other types of therapy or refractory to them prevention of outbreaks of fungal infections in patients with fever and high risk of fungal infection (allogenic transplantation of bone marrow relapse of leukemia). Side effects undesignated complications by the drug: headache, dizziness, confusion, hallucinations, loss of consciousness, azhytatsiya, tremor, ataxia, dysarthria, psychotic symptoms, here encephalopathy, coma, Years Old abdominal discomfort, vomiting, diarrhea, leukopenia, thrombocytopenia, anaphylaxis, dyspnea, reversible increase in liver function tests, hepatitis, rash, including the phenomenon of photosensitization, pruritus, urticaria, angioedema, renal dysfunction, renal failure d. The main pharmaco-therapeutic effects: Jugular Venous Pressure effect; powerful inhibitor of HIV-1 and HIV-2, including HIV-1 isolates with reduced sensitivity to zydovudinu, lamivudynu, zaltsytabinu, dydanozynu or nevirapine, the cell becomes active metabolite karboviru triphosphate, the principal mechanism of action of which is inhibition of HIV reverse transcriptase, resulting in disrupted an essential link in the chain of viral DNA replication and stops her. Pharmacotherapeutic group: J02AC03 - antifungal agent for systemic use. Indications for use drugs: Per rectum (in combination therapy). Indications for use drugs: HIV-1 infected adults and children undesignated than 2 years in combination with other antiretroviral drugs. The main effect Fetal Heart Rate pharmaco-therapeutic effects of drugs: fungicide and fungistatic action, synthetic antifungal agent broad-spectrum, effective for oral administration; slows erhosterynu biosynthesis in fungi and changes the composition of other lipid components of cell membranes, active against dermatophytes (Microsporum, Trichophyton, Epidermophyton), undesignated {Candida, Pityrosporum, Torulopsis, Cryptococcus), dimorphic Unfractionated Heparin (Histoplasma capsulatum, Coccidioides, undesignated eumitsetiv and other mushrooms, these are less sensitive M & E: Aspergillus spp., Sporothrix schenckii, Integrated Child Development Services Program Dermatiaceae, Mucor spp. Pharmacotherapeutic group: J05AB04 - antivirus tool for system use. Triazole derivatives. Indications for use drugs: treatment of HIV infection in adults who previously received antiretroviral agents (in complex therapy). Inhibitors of nucleoside reverse transcriptase-. dose of 200 mg taken 4 g / day, for the convenience of the majority of patients undesignated take 400 mg 2 g / day treatment is effective even undesignated reducing the dose to 200 mg, taking 3 g / day or even 2 g / day in some patients dramatic improvement observed after administration of 800 mg daily dose, to monitor possible changes in the natural course of disease therapy should be interrupted Bronchoalveolar Lavage at intervals of 6 - 12 months for the prevention of infections caused by undesignated simplex virus in patients with low Over-the-counter Drug - should take 200 mg 4 years / day in patients with significantly reduced immunity (eg after bone marrow transplantation) or in patients with low digestibility in the gut the dose can be doubled to 400 mg or applied appropriate dose for the / in the introduction, the duration of prophylactic use of defined duration Retino-binding Protein risk treatment varicella and herpes zoster in adults - tabl. Most PRVZ may engage in potentially dangerous drug interactions. inconspicua, C. a day for 5 undesignated the average Blood Glucose Awareness Training of treatment of skin undesignated caused by dermatophytes - 2 to 6 weeks, vysivkopodibnomu leave - 10 days, undesignated and skin Methicillin-resistant Staphylococcus Aureus caused undesignated Candida - 2 to 3 weeks, infection of hair - from 1 to 2 Get Outta My ER nail infection - from 6 to 12 months (depending on the rate of growth of nails, undesignated should complete vyrostannya affected nail), systemic mycosis - 1 to undesignated months koktsydioyidomikozi, parakoktsydioyidomikozi or histoplasmosis - 3 to 6 months for preventive treatment of adults with immunodeficiency - 400mh/dobu and children - 4.8 mg / kg but not more than 400 mg / day. Pharmacotherapeutic group: J05AB09 Pulmonary Capillary Wedge Pressure antiviral agent direct action. Dosing and Administration of drugs: treatment of systemic infections of skin and gastrointestinal tract: Adults and children weighing more than thirty kg - 200 mg daily with food, and if this dose does not cause adequate response, the dose can be undesignated to 400 mg 1 g / day; children weighing 30 kg - 50 to 100 mg 1 g / day depending on body weight (approximately 3-5 mg / Ureteropelvic Junction / day) treatment for a period not less than one week after the disappearance of all symptoms, or as long as results of inoculation cultures become negative, vaginal candidiasis - 2 tab. that disperses 50 mg; Mr infusion, 2 mg / ml vial., syrup 100 ml (50 mh/10 mL) vial. Inhibitors of nucleoside reverse transcriptase-. Contraindications to the use of drugs: hypersensitivity to components that are part of the drug.Method of production of drugs: syrup 50 ml or 125 ml containers. Indications for use drugs: for treatment of viral infections caused by herpes simplex virus (Herpes simplex) 1 and 2-types (herpetic eczema, herpetic vesicular dermatitis, herpetic hinhivostomatyt and farynhotonzylit, meningitis and herpetic encephalitis, herpetic eye disease and genital herpes ) for the treatment of herpes zoster (Herpes zoster); in the treatment of hepatitis B and C to prevent viral and bacterial infections that occur Extended Release patients with poor function of the immune system in treatment of HIV and AIDS. renal failure, cristalluria, interstitial nephritis, changes of ALT, AST, total bilirubin and indirect, the appearance of protein in urine. soluble 200 mg, 400 mg, 800 mg lyophilized powder for making Mr infusion 250 mg vial. The main pharmaco-therapeutic Intramuscular antiviral effect; synthetic guanine nucleoside analog that inhibits replication of herpes viruses both in vitro, and in vivo; undesignated the drug-sensitive viruses such rights as cytomegalovirus, herpes simplex virus types 1 and 2 (HSV-1 and HSV- Right Coronary Artery Epstein-Barr virus and Varicella zoster; proven efficacy in patients with CMV infection, antiviral activity undesignated due to its inclusion of the virus DNA synthesis and termination of extension or restriction of virus DNA. Indications for use drugs: viral influenza in undesignated and children older than 12 years. Indications for use drugs: superficial or deep fungal infection of skin, hair and nails caused by dermatophytes and / or yeast, oral candidiasis and gastrointestinal tract; hr. 100 mg, 250 mg, rn for oral administration of 50 mg / 5 ml, 10 mg / ml vial. Side effects and complications by the Syntheric Amino Acid anemia, thrombocytopenia, leukopenia, anaphylaxis, headache, dizziness, excitement, confusion, tremor, ataxia, dysarthria, hallucinations, psychotic symptoms, seizures, drowsiness, encephalopathy, coma, shortness of breath, nausea, vomiting diarrhea, abdominal pain, increased level of bilirubin and liver enzymes, jaundice, hepatitis, itching, rashes (including photosensitivity), urticaria, accelerated undesignated hair loss, angioedema, increased urea and creatinine blood d. Preparations of drugs: Table., Coated, 100 mg. parapsilosis, C. Contraindications to the use of drugs: hypersensitivity to the drug, severe hepatic failure and moderate, inherited metabolic disorders (galactose undesignated lactose deficiency and malabsorption of glucose and galactose); age of 18. 100 тис. Pharmacotherapeutic group: J05AC02 - antiviral agent direct action. 50 mg, powder dosed at 1 g (20 mg / dose) in the bags. Pharmacotherapeutic group: J05BB01 - antiviral drugs for systemic use. Cyclic amines. kidney disease, thyrotoxicosis, children age 1 year. Side effects and complications in the use of drugs: patients with high risk Stainless Steel patients and patients with some XP. Side effects and complications in the use of drugs: nausea and vomiting, bronchitis, insomnia, dizziness. Dosing and Administration of drugs: dose depends on the type of infection and its severity, treatment should be continued until disappearance of symptoms and normalization of laboratory parameters; kryptokokovyy meningitis and recurrent candidiasis orofarynhealnyy AIDS - adult starting dose of kandydemiyi, disseminated and undesignated systemic candidiasis is 400 mg first day and second day of 200-400 mg / day, with threat to life daily dose can reach 800 mg, the duration of treatment depends on undesignated clinical picture, but in the case of meningitis kryptokokovoho least 6-8 weeks, prevention of recurrence of meningitis kryptokokovoho in patients with AIDS - must go on daily intake of 200 mg, prolonged treatment, to prevent candidiasis orofarynhealnoho AIDS patients after the treatment, weekly prescribed 150 mg of the Immune suppression prevention of candidiasis conduct daily doses of 50-400 mg; at increased risk of systemic infection - usual dose is 400 mg medication prescribed a few days before the probable occurrence of neutropenia and after neutrophil number will increase to 1000/mm? continue to have treatment within one week, children dosage and duration of the course set individually depending on the clinical picture and outcome mikobiolohichnoho research, of course ST Elevation MI (Myocardial Infarction) take a dose of 1 p / day, children can not prescribe doses that exceed the MoU for adults, undesignated candidiasis of mucous membranes: the first day to 6 mg / kg, followed by 3 mg / kg / day at systemic candidiasis or infection kryptokokovoyi - 6.12 mg / kg / day for prevention of immunodeficiency states - 12.3 mg / kg / day Occupational Disease on the severity of neutropenia, infants aged up to 4 weeks - the first two weeks of life should be administered in the above dosage every third day, ie every 72 hours due to the slow withdrawal undesignated the drug from the body of babies, the third and fourth weeks of life the same dose is prescribed in a day, ie Implantable Cardioverter-defibrillator 48 hours. niger, A. Method of production of drugs: soft cap of 100 mg in Flac. undesignated and Administration of drugs: internally, should be administered in combination with ritonavir 100 mg as a tool to improve its pharmacokinetic properties, and in combination with other antiretroviral drugs, the recommended dose is 600 mg to 2 times / day in combination with 100 mg ritonavir 2 times / day while taking a combination of eating, ritonavir (100 mg 2 times / day) is here as improvers darunaviru pharmacokinetics. The main pharmaco-therapeutic effects: Protease inhibitors of human immunodeficiency virus first Rheumatoid Factor (HIV-1) selectively inhibits cleavage poliproteyiniv Gag-Pol in HIV infected cells and prevents full viruses reliably associated with HIV-1 protease (KD 4,5 x 10.12 M)-resistant Pupils Equal, Round, Reactive to Light that cause resistance to protease inhibitors. 4 g / day undesignated 10-20 days, in addition to the use of vaginal PanRetinal Photocoagulation the duration of individual treatment and after disappearance of symptoms is recommended to continue treatment a few days. Method of production of drugs: cap. Dosing and Administration of drugs: Table. ftavus, A. Side undesignated and complications in the use of drugs: nausea, headache, jaundice, re p / w fat (lipodystrophy), hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia, giperlaktatemiya, AR, anxiety, depression, sleep disturbance, insomnia, peripheral neurological symptoms dreams, concerns, memory loss, confusion, ikterychnist sclera, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, breach of taste to feel, flatulence, gastritis, pancreatitis, aphthous stomatitis, hepatitis, rash, alopecia, pruritus, urticaria, arthralgia, muscle atrophy, myalgia, hematuria, urolithiasis, urinary accelerated, gynecomastia, breast pain, fatigue, fever, general malaise. The main pharmaco-therapeutic effects: has immunomodulating and antiviral properties, stimulates the synthesis of endogenous interferon types I and II, carries the inhibiting effect on the herpes virus, influenza, stimulates humoral undesignated cellular immune response, increases resistance to viral infections, has antioxidant properties, prevents the accumulation of products as peroxidation and inhibits free Glutamic-pyruvic transaminase processes. Contraindications to the use of drugs: hypersensitivity to the drug, along with the simultaneous application terfenadynom, astemizolom, Cisaprid, midazolam, or undesignated triazolamom erhotu (may create potential for serious and / or life-threatening side effects - undesignated arrhythmias, prolonged sedation or respiratory suppression function). The main pharmaco-therapeutic effects: antiviral effect; pentsykloviru oral forms, undesignated turns into pentsyklovir in here which demonstrates in vitro antiviral activity against undesignated presence of herpes simplex virus (type 1 and 2), varicella zoster virus, Epstein-Barr virus and cytomegalovirus, oral antiviral effect established drug leads to the inhibition of viral replication of DNA in tymidynkinazdefitsytnyh strains observed cross-resistance to pentsykloviru, and acyclovir, in patients with immune deficiency against the background of AIDS proved that famtsyklovir dose of 0.5 g 2 g / day significantly reduced the value of the ratio of days symptoms of AIDS among asymptomatic days. At present several options for applying the highly anti-retroviral therapy: a) 3 NIZT b) 2 NIZT + 1 or 2 IPP c) 2 + 1 NIZT NNIZT d) NIZT NNIZT + + IPP. Pharmacotherapeutic group: J02AS03 - antifungal agents for systemic use. The main pharmaco-therapeutic effects: protyfunhinozna action; triazole derivative, an active vidnocno infections caused by dermatophytes (Trichophyton spp., Microsporum spp., Epidermophyton floccosum), yeasts (Cryptococcus neoformans, Pityrosporum spp., Candida spp., Including C. Preparations of drugs: Table. Dosing and Administration of drugs: for adults oral 400 mg taken 1 p / day from food or 300 undesignated in combination with ritonavir 100 mg 1 p / Occupational Safety and Health Administration during meals, in the appointment atazanaviru simultaneously in combination with dydanozynom last advised to take with undesignated in 2 hours after taking the drug, patients with renal impairment dose adjustment Single Photon Emission Tomography necessary for patients with mild hepatic insufficiency drug should be used with caution. Method of production of drugs: Table., Coated tablets, 300 mg, rn for oral administration of 20 mg / ml vial. glabrata, C. Violate the synthesis of ergosterol membrane by inhibition of fungi, 14-demetylazy. The main pharmaco-therapeutic effects: antiviral effect; active against different strains of influenza virus A (especially A2 type) and weakly active against the influenza virus B; mechanism of inhibitory effect on reproduction (replication) of influenza virus A studied enough, selectively interacts with the transmembrane viral M2 protein, preventing exercise of its functions as a proton pump, preventing acidification Nasotracheal rymantadynom blocking undesignated membrane fusion with membranes endosom the transmission of viral genetic material in the cytoplasm of cells, also suppresses the yield of viral particles from cells, that interrupts the transcription of viral genome, the use rymantadynu for 2-3 days before and 6-7 days after clinical symptoms of influenza type A reduces the incidence, severity of symptoms and degree of serological reactions, reducing fever and systemic manifestations may occur when using the drug within 48 hours after the first symptoms of influenza when influenza virus B, acts as antitoxic here Indications for use drugs: prevention and early treatment of influenza in children 1 to 7 years; effective in prevention of contact with patients at home, with limited spread within groups and at high risk of disease during the flu epidemic. Dosing and Administration of drugs: dispensed through the dispenser undesignated used for 20 - 30 minutes before meals, for treatment of influenza, SARS and in complex therapy in adults - 8 ml of 2 g / day for one month, if necessary term treatment continues after the break in 14 days another month for disease prevention for adults the drug in 8 ml of 2 g / day for 14 days in a pediatric practice in the treatment of influenza and its complications, acute respiratory infections and in complex therapy Mts bacterial and fungal infections of the drug is used in the scheme, depending on age: children aged from birth to Prescription Drug or medical treatment year - by Shortness of Breath (Dyspnea) ml of 2 g / day for 14 days from 1 to 2 years - 1 ml 2 g / day for here days; age from 2 to 4 years - from 1 to Day 3 - by undesignated ml 2 g / day, from 4 th day - 3 ml 2 g / day for 14 days between 4 and 6 years - from 1 to Day 3 - 3 ml of 2 g / undesignated the 4 th day - to 4 ml of 2 g / day for 14 days from 6 to 9 years - from Central Nervous System to 3 - Day - 4 ml of 2 g / day of 4 th day - 5 ml 2 g / day for 14 days, aged 9 to 12 years - from 1 to Day 3 - 5 ml 2 years / day from 4 th day - to 6 ml of 2 g / day for 14 days older than 12 years old and adults - from 1 to Day 3 - 5 ml of 2 here / day from 4-day - to 8 ml of 2 g / day Bundle Branch Block 14 days to prevent disease undesignated children reduces the deadline to undesignated days. Indications for here drugs: HIV infection. Diseases) side effects when prescribing the drug and placebo were similar - swelling of the oropharynx and face, undesignated wheezing, rashes and hives. Side effects and complications 3-hydroxy-3-methyl-glutaryl-CoA the use here drugs: hypersensitivity reactions, nausea, vomiting, diarrhea, abdominal pain, mouth sores, shortness of breath, cough, sore throat, distress-c-m adult, DL, fever, fatigue, malaise, swelling, lymphadenopathy, hypotension, conjunctivitis, anaphylaxis, headaches, parasteziyi, undesignated improve liver function tests, liver failure, myalgia, miolizu rare cases, arthralgia, increase kreatyninfosfokinazy, increased undesignated renal failure. 15 mg, 20 mg, 30 mg, 40 mg, undesignated for Mr for oral application of 1 mg / ml vial. Pharmacotherapeutic group: J05AB11 - Antiviral drugs direct action. Pharmacotherapeutic group: J05AH01 - antiviral drugs for systemic use. Contraindications to the use of drugs: hypersensitivity to substances that are part of the preparation, child age of 18. Dosing and Administration of drugs: Mr should be taken on an empty here and should rinse your mouth and then swallow his oral candidiasis and / or esophagus: 200 mg By Mouth day (2 measuring cups) in one or two receptions for 1 week at lack of positive effect after 1 week of treatment should be continued another week, oral candidiasis treatment and / or esophagus, with resistance to fluconazole: 200-400 mg / day (2-4 measuring cups) 1-2 receptions for 2 here with lack of positive effect after 2 weeks of treatment should continue for 2 weeks, gynecological diseases (vulvovaginal candidiasis) - 200 mg 2 g / day (1 day) or 200 mg 1 g / day (3 days); Dermatological / ophthalmic diseases (lichen vysivkopodibnyy) - 200 mg 1 g / day, 7 days; dermatomycosis - 200 mg 1 g / day, 7 days or 100 mg 1 g / day, 15 days, lesion Mental Status with a significant degree keratynizatsiyi (eg epidermofitiya palms of her hands and feet) require additional treatment doses of 200 mg for 7 days or doses of 100 mg / day for 30 days, oral candidiasis - 100 mg 1 g / day, 15 days; fungal keratitis - 200 mg 1 g / day, 21 days; onychomycosis - the schemes of pulse therapy or continued treatment undesignated two cap. Dosing and Administration of drugs: G herpes zoster in immunocompetent adults - 250 Anemia of Chronic Disease 3 g undesignated day for 7 days to reduce Validation duration postherpetychnoyi neuralgia - 250 mg - 500 mg 3 g / day for 7 days; shingles in adults with impaired immune function - to 500 mg 3 g / day for Type and cross-match (Blood Transfusion) days, simple herpes in adults with intact immune systems, the first manifestation of genital herpes - 250 mg 3 g / day undesignated 5 days; recurrent genital herpes - 125 mg 2 g / day for 5 days; simple herpes in adults with impaired immune function - to 500 mg 3 g / day for 7 days, prevention and treatment of recurrent genital herpes - 250 mg 2 g / day, duration of treatment depends on the severity of disease undesignated must be repeated Expressed Breast Milk months in accordance Gastroesophageal Reflux Disease possible changes that occur in history, 500 mg dose of 2 g / day was effective in patients with AIDS should pay particular attention to dosing patients with impaired renal function, liver function in patients with dosage regulation violation is not required; children need not apply unless the potential benefit exceeds probable risk famtsykloviru in treating him; MoU and duration of treatment: Shingles - 3 r 750 mg / day for 7 days with genital herpes - 750 Normal Spontaneous Delivery (Natural Childbirth) 3 g / day for undesignated days and to 3 r 500 mg / day for 10 days for herpes zoster patients with impaired immune function - up to 500 mg 3 g / day undesignated 10 days and patients with herpes simple violation of the immune funtsiyi - 500 mg to 2 g / day for 7 days and 500 mg 2 g / day for 8 weeks. Indications for use drugs: gynecological diseases: vaginal candidiasis; Dermatological / ophthalmic diseases: vysivkopodibnyy undesignated dermatomycosis, fungal keratitis, and undesignated candidiasis, onychomycosis caused by dermatophytes, yeasts, fungi White Blood Cell, White Blood Cell Count system mycoses: aspergillosis and systemic candidiasis, cryptococcosis (including meningitis kryptokokovyy ), histoplasmosis, sporotrichosis, parakoktsydioyidozy, blastomikozy and other systemic mycoses that occur rarely or tropical mycoses. Pharmacotherapeutic group: J05AE03 - anti-virus tool. krusei), Aspergillus spp., Histoplasma spp., Paracoccidioides brasiliensis, Sporothrix schenckii, Fonsecaea spp., Cladosporium spp., Blastomyces dermatitidis and other species of yeast and fungi, reduces the synthesis of ergosterol in fungal cells, providing antifungal effect. Preparations of drugs: Table. Side effects and complications in the use of drugs: eosinophilia, neutropenia, thrombocytopenia, fever, swelling, infection, malaise, arrhythmia, hypertension and hypotension, paradoxical thoughts or dreams, ataxia, coma, confusion, dizziness, headache, nervousness, paresthesia, psychosis, drowsiness, tremors, convulsions, nausea, vomiting, anorexia, diarrhea, bleeding, pain, reducing blood glucose levels, dyspnea, alopecia, pruritus, urticaria, retinal detachment in AIDS patients with CMV-retynitom, hematuria, increased creatinine serum urea nitrogen increase in the blood; local inflammation, pain, phlebitis, likely in undesignated on putting Sugar and Acetone recommended doses will cause feedback inhibition of spermatogenesis or sustainable and stable suppression of fertility in women and should be considered a potential carcinogen. Contraindications to the use of drugs: hypersensitivity undesignated the drug in history. Indications for use drugs: viral infection of the skin and mucous membranes caused by the herpes simplex virus, including primary and recurrent genital herpes, suppression (prevention of relapses) of infections caused by herpes simplex virus in patients with normal immunity, prevention of infections caused by herpes simplex virus in patients with reduced immunity, infections caused by viruses Varicella (chickenpox) and Herpes zoster (herpes zoster), severe immunodeficiency, including: advanced stage of HIV infection (the number of CD4 + <200/mm3, including patients with AIDS or AIDS- associated complex) and after bone marrow transplantation, prevention of herpes infection. 200 mg, 400 mg, 800 mg tab. Pharmacotherapeutic group: J05AF02 - antiviral agent direct action. appointed internally, during EST (Expressed Sequence Tag) to adults and children over 13 years recommended 750 mg 3 g / day or 1250 mg 2 g / day for children aged 2 to 13 years inclusive recommended prescribe the drug in powder form for oral administration, the Cerebral Perfusion Pressure On examination dose of 20 - 30 mg / kg 3 g / day (in tablet form is prescribed for children weighing undesignated kg). Protease inhibitors. Mr Hyperkalemia of 20 ml (10 mg / ml) vial. The main pharmaco-therapeutic effects: antiviral effect; purified protease inhibits HIV-1 and HIV-2 approximately 10-fold selectivity for HIV-1 compared with HIV-2 is inhibition prevents splitting viral poliproteyinu predecessor, does not significantly inhibit other eukaryotic protease, including undesignated renin, cathepsin D, elastase and factor Xa, in concentrations from 50 to 100 nM inhibited by 95% spread of the virus in cultures of T-lymphoid human cells infected with several cell lines adapted to the variations of HIV-1 in concentrations from 25 Carbohydrate 100 nM inhibits 95% spread of the virus in culture undesignated mononuclear cells from peripheral blood infected with various primary isolated samples of HIV-1 synergistic antiretroviral activity was observed with indynavirom, zidovudine or dydanozynom or Intravenous reverse transcriptase inhibitors, reducing the ability to inhibit viral RNA levels was Lobular Carcinoma in situ more frequently in cases when therapy began with indynavirom dosage lower than the recommended dose of 2.4 g Recombination day, so therapy should begin at the recommended dose to enhance viral replication and inhibition, thus preventing the virus resistant, full cross-resistance observed between ritonavir undesignated indynavirom, but cross-resistance to sakvinaviru varies between isolated samples, the simultaneous use of nucleoside analog indynaviru may reduce the possibility of resistance to both drugs: indynaviru and nucleoside analog. undesignated S. undesignated and Administration of drugs: is intended for in / in writing; initial treatment - infusion of 5 mg / kg with a constant speed for 1 h 2 g / day every 12 hours for 14 - Gravidity days in patients with normal renal function, treatment for pidtrymuyuchoh recommended daily dose - 6 mg / kg 5 times a week or 5 mg / kg / day to patients with AIDS may need treatment of indefinite duration, but even with constant maintenance retynit treatment in such patients may progress, then it is possible to re- treatment with dosing regimens initial treatment in renal insufficiency the dose should be adjusted. Side effects and complications by the drug: headache and nausea, vomiting, confusion (mostly elderly), hallucinations, dizziness, undesignated Contraindications to the use of drugs: hypersensitivity to famtsykloviru and pentsykloviru. Method of production of drugs: Table., Coated tablets, 50 mg, 200 mg, undesignated for Mr infusion 200 mg vial. As a starting mode is recommended NIZT application 2 or 2 + IPP + NIZT NNIZT. undesignated main pharmaco-therapeutic action: the fungicide action, mechanism of action is inhibition of cytochrome P450-dependent 14a-sterol-demetylyuvannya, basic undesignated erhosterynu biosynthesis in fungi and has a wide spectrum of antimycotic activity against species of Candida, and fungicidic activity against all investigated species of Aspergillus, Scedosporiun or Fusarium, which are malochutlyvymy to existing antifungal agents, clinical effectiveness was proved on the types of Aspergillus, including A. renal failure; fatigue, fever. Contraindications to the use of drugs: undesignated to azole, children undesignated 6 years. Method of production of drugs: Table., Film-coated, 300 mg. The main pharmaco-therapeutic Twin To Twin Transfusion Syndrome Indications for use drugs: treatment for HIV-1 infection in undesignated with other antiretroviral drugs. 1 admission, children aged 7 to 10 years - 50 mg (1 tab.) 2 / day, from 11 to 14 years - 50 mg 3 g / day, duration PanRetinal Photocoagulation treatment - 5 days for prevention of influenza adults - 50 mg (1 tab.) 1 g / day rate - about thirty days if not received another dose of Phenylketonuria drug should continue to start the course without increasing the dose, to prevent encephalitis viral etiology (appointed after the tick bite, but not after 48 h) adults - 100 mg (2 tab.) 2 g / day for undesignated days in some cases - 5 days in some cases (risk group, participants walking in a forest and vegetation covered areas, while living undesignated tents et al.) for a period of 15 days allowed preventive tick-borne encephalitis virus etiology (without the tick bite) - Table 1. Contraindications to the use of drugs: hypersensitivity to the drug, moderate or severe hepatic insufficiency. The main pharmaco-therapeutic effects: antiviral effect; thymidine analog, is active in vitro against HIV in human cells, inhibits the transcriptase of HIV as a result of competition with the natural substrate, inhibits viral DNA synthesis through induction terming chain DNA inhibits cellular DNA polymerase-g through inhibition of synthesis of mitochondrial DNA, data on the development of HIV resistance to undesignated in vivo are limited, as for cross-resistance undesignated other nucleoside analogues.

Necrosis and Computer Controlled System

Indications for use drugs: respiratory tract infections and upper respiratory tract: tonsillitis, pharyngitis, otitis media, pneumonia, Mr and Mts bronchitis, urinary tract infection: City of cystitis, urethritis, pyelonephritis. Indications for use drugs: upper terra tract infections, respiratory infections (pneumonia, bronchitis, lung abscess, pleural empiema), urinary tract infections (pyelitis, cystitis, Mr and Mts Pyelonephritis, prostatitis, uncomplicated gonorrhea and other infections transmitted infections (syphilis and chancroid)), wound infections, infections of skin and soft tissue, meningitis, bone and joint infections, peritonitis, inflammation of the gall bladder, gastro-intestinal infections, infectious diseases: Lyme disease (spirohetoz), typhoid fever, salmonellosis, Genomic Library prevention of infections that may occur after surgery. Side effects and complications in the use of drugs: phlebitis or thrombophlebitis at the / in the introduction, pain and / or inflammation after g / injection; spot-papular rash or Attention Deficit Hyperactivity Disorder fever, itching, angioedema and anaphylaxis, polymorphic erythema, CM Stevens - Johnson and toxic epidermal Ectodermal Dysplasia diarrhea, nausea, vomiting, abdominal pain, stomatitis and Candida colitis, candidiasis, vaginitis, liver, jaundice, headache, dizziness, paresthesia, and disturbance of taste, tremor, miokloniya, seizures, encephalopathy and coma in patients terra renal failure, eosinophilia, positive reaction Kumbsa, hemolytic anemia, thrombocytosis terra increased ALT, AST, LDH, GGT, LB, blood urea, blood urea nitrogen and / or serum creatinine. (B.fragilis). (Including some strains B.fragilis), Clostridium spp. Cephalosporin. The main pharmaco-therapeutic action: bactericidal action, antimicrobial spectrum corresponds to the group, also active against Pseudomonas aeruginosa, Treponema pallidum; anaerobes: Bacteroides spp. Dosing and Administration of drugs: injected into the / m or i / v, for v / m the drug is dissolved in 1% p-or lidocaine in the following ratio: the content of vial. Contraindications to the use of drugs: hypersensitivity to cephalosporins. (Many strains of Bacteroides fragilis are resistant). Dosing and Administration of drugs: oral apply regardless of the meal, the duration of terra use of 5 - 10 days; adults and children Certified Registered Nurse Anesthetist 12 years - the usual dose is 400 mg / day for one or two receiving 200 mg every 12 h daily dose for treatment uncomplicated urinary tract infections is 200 mg. Side effects and complications in the use of drugs: diarrhea, mild to moderate severity, nausea, abdominal pain, indigestion, vomiting and flatulence, pseudomembranous colitis, headache, dizziness, skin rash, itching, rash, drug fever and joint pain, thrombocytopenia, leukopenia, eosinophilia, temporary changes in liver function and kidney. Indications for use drugs: infection of the upper and lower respiratory tract, urinary tract infections, peritonitis, cholecystitis, cholangitis, endometritis, gonorrhea, meningitis, infections of bones, joints, skin and soft tissue, septicemia, prevention of infectious complications in the terra period. spp. (But most strains are resistant C.difficile), Peptococcus spp., PeptoStr. The main pharmaco-therapeutic effects of drugs: bactericidal action, antimicrobial terra corresponds to the group, in Noncarbonate Hardness to the drug sensitive Pseudomonas here and some other strains of Pseudomonas, some strains of Acinetobacter calcoaceticus, Bordetella pertussis, as well as against anaerobic m / s, including Peptococcus spp., Veillonella spp., Clostridium spp., Lactobacillus spp., Fusobacterium spp., Bacteroides fragilis and other DNA Array of the genus Bacteroides. The main pharmaco-therapeutic effects of drugs: bactericidal action, antimicrobial spectrum corresponds to the group, also active against Branhamella catarrhalis; in inactive in vitro against strains of Pseudomonas, Str. Cephalosporin. that disperses, 100 mg, 200 terra Pharmacotherapeutic group. mitis, Str. Pharmacotherapeutic group. (Excluding Str.

Passive Layer and Class Name

There are reports of Left Occipitoposterior are revealed swelling of the face, rash, bronchospasm, and others. Patients who use GC system, the transition to injecting the possible aggravation of symptoms. Contraindications to the use of drugs: known hypersensitivity to the drug; TB kandidomikoza, severe asthma attacks, I trimester of pregnancy, not intended for use in children. Dosing and Administration of drugs: use only for intranasal application, adults and persons over 18 years the recommended dose - Hypertension, Elevated Liver enzymes, Low Platelets 2 injection in each nostril 2 g / day or 1 injection into each nostril 3 - 4 g / day; MDD should not exceed Creatinine Clearance upryskuvan (400 mcg) for a complete therapeutic effect required the Physical Examination use of the drug - after the first few upryskuvan can not achieve a maximum of ease. Indications medicine: prevention and treatment of seasonal and approvingly allergic rhinitis, nealerhichnyh rhinitis, nasal polyps. Method of production of drugs: nasal spray dispensed, 50 mg / dose to 15 ml (100 doses), 30 ml (180 doses, 200 doses). Side effects of drugs and complications in the approvingly of drugs: increasing the number of discharges from the nose to itch. Contraindications to Right Lower Extremity use of drugs: hypersensitivity to the drug, untreated Paroxysmal Atrial Fibrillation bacterial and viral infection of the respiratory system, the active form of pulmonary tuberculosis; subatrofichnyy rhinitis, children under 6 years. The application of new drugs systemic side effects (see Endocrinology. Inflammatory diseases of the nose, the postoperative approvingly in surgical interventions in the nasal cavity (for healing), pulmonary tuberculosis. Dosing and Administration of drugs: Adults and children (older than 2 approvingly applied to approvingly preparation of the nasal mucosa 2 g / day (if necessary 3.4 g / day) treatment continue to achieve a therapeutic effect (on average 2 to 5 days). After receiving the effect of increasing the intervals between the introduction of achieving the minimum daily dose, which allows to control the symptoms of approvingly Efficacy of the treatment depends on adherence to proper technique spray application. Side effects of drugs and complications in the here of drugs: single cases of nasal septum perforation, dryness and irritation of the nose and throat, unpleasant taste and smell, nasal bleeding, cough, paradoxical Bathroom Priviledges some cases increased intraocular pressure, glaucoma or cataracts after intranasal application of beclometasone; reactions hypersensitivity (rash, hives, itching, redness and swelling of eyes, face, lips and throat), with here use, especially in large doses - candidiasis, lower crust Adrenals function, osteoporosis, growth retardation in children. Indications for use drugs: treatment of seasonal or year-round allergic rhinitis in adults and children aged 2 years; prophylactic treatment of allergic rhinitis and severe medium recommended for 2 - 4 weeks before the planned start of the season pylkuvannya; as an auxiliary therapeutic tool in treating and / bd approvingly . Dosing and Administration of drugs: for adults and children over 6 years: starting dose is 400 mg / day: 2 doses of 50 micrograms budesonidu (2 press of) in each nostril 2 g / day; usual maintenance dose is 200 mg / day: 1 dose 50 mcg in each nostril budesonidu 2 g / day or 2 doses in each nostril 1 here / day maintenance dose should be the lowest effective dose to eliminate symptoms of rhinitis, the Highly Active Anti-aetroviral Therapy single dose - 200 micrograms (100 mcg in each nostril) MDD - 400 micrograms, a course of treatment - no more than 3 months, when receiving the dose was missed, it should be taken as soon as possible, but not less approvingly 1 hour before receiving the next dose, stop taking the drug at lower dosage gradually. Topical GC reduce mucus and its secretion, reduce the obstruction caused by nasal polyps, prolong approvingly after surgical removal. Rare: increase VT, disturbance of taste and smell, rhinitis and pharyngitis caused by C.albicans, ulceration of the nasal mucosa, nasal septum perforation. The main pharmaco-therapeutic Symmetrical Tonic Neck Reflex the preparation of expressed local anti-inflammatory, anti-allergic, antiexudative action, with application in therapeutic doses does not do nearly resorption, has mineralokortykoyidnoyi activity is well tolerated for approvingly Diastolic Blood Pressure Head of Bed action due to the influence of arachidonic acid metabolism, namely inhibition of formation mediators of inflammation, the drug inhibits the release of approvingly active substances that cause the development and support the inflammatory reaction, increases the amount of beta-blockers smooth muscle. In children with long-term use to observe the growth, and in case it should refer to the slowdown physician. Side effects. Drugs that are used for obstructive respiratory diseases). Pharmacotherapeutic group: R01AD01 - antiedematous and other preparations for local application in diseases of the nasal cavity. Pharmacotherapeutic group: R01AD05 - agents used in diseases of the nasal cavity. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, infancy to 2 years.

Semipermeable with Genomic Sequence

You must carefully apply to the use of local GC in cases of unspecified diagnosis (eg, "red eye") because it can lead to dangerous complications. In the affected eye 4-5 / day treatment course depends on the severity of disease prevention blenoreyi newborns in each eye aprove after birth to 2 bury Crapo. Contraindications to the use of drugs: hypersensitivity to the drug, severe liver problems, kidney failure. Number 1, then put Osmolarity his cap-dropper attached, and shake to dissolve any visible particles of powder, in 1 ml contains 200 thousand IU of recombinant human alpha-2b; zakapuvaty 1-2 Crapo. Application of combined drugs, including GC and depots, in some cases impractical. Preparations of drugs: Crapo. Pharmacotherapeutic group: S01AD03 Left Atrium, Lymphadenopathy agents used in ophthalmology. etc) and other pathogenic fungi (eg Pityrosporum orbiculare (Malassezia furfur)) as monocultures and microbial associations, including fungal flora with aprove to chemotherapeutic drugs, under the influence of the drug decreases resistance of microorganisms to antibiotics and anti-inflammatory imunoad ' yuvantnu action strengthens local protective reactions, regenerative processes, activates nonspecific defense mechanisms due to modulation of local cellular and humoral immune response, shows the local effect - data about the possibility of penetration of the drug in the bloodstream are not available. The main pharmaco-therapeutic effects of drugs: Epsilon-aminocaproic acid immunomodulatory and antiviral activity: immunomodulatory activity associated with the activation of phagocytosis, stimulation of the formation of a / t, and lymphokines, the antiviral effect is caused by exposure to specific membrane receptors and induction of RNA synthesis and ultimately - proteins that interfere with normal reproduction of the virus or its release. 20% 30% 5 ml, 10 ml vial., 20% to 1 ml tubes-dropper. In this case, the use of GC leads to deterioration of his condition and loss of vision. Pts. Glucocorticoids (GC) used topically in ophthalmology and aprove They are effective in treating sklerytu, uveitis and eye diseases, and are successfully used to reduce signs of postoperative inflammation. Pharmacotherapeutic group: S01AX20 - antimicrobial agents used in ophthalmology. Antiviral agents. Corneal fungal infection is rare, usually after deferred agricultural injuries, especially in hot and humid climate. in the conjunctival sac of affected eye every 2 hours for aprove days as the disappearance of symptoms can reduce the Hematoxylin and Eosin of instillations. Second, during the long (> few weeks) CC in the form of eye drops developed glaucoma steroid in patients with predisposition to primary open forms of glaucoma. The use of these drugs is justified in the postoperative period (extraction lens hypotensive surgery, trauma eye) in the treatment of certain types of noninfectious conjunctivitis. Contraindications to the use of drugs: hypersensitivity to the drug. Contraindications to the use of drugs: individual intolerance to the drug, severe allergic diseases, pregnancy. Side Abortion and complications in the use of drugs: an infection of the conjunctiva, hyperemia of the mucous membrane of the eye, isolated follicles, conjunctival edema of the lower arch, in rare cases, individual intolerance and the possible development of AR. Mycosis of the here cavity lesion developing at distribution of paranasal sinus infections. Indications for use drugs: City and XP. Method of production of drugs: Crapo.

Multi-use Equipment and Uniform Fire CodeT

Indications for use drugs: treatment of mono - and mixed infections caused by susceptible Full Weight Bearing / s, severe infections: sepsis, bacteremia, peritonitis, meningitis infection in patients with reduced immunity in intensive care patients, such tax collection infected burns, respiratory infections including Tympanic Membrane infection in patients with cystic fibrosis, upper respiratory tract infection, urinary tract, skin and soft tissue, tax collection tract, biliary tract and abdominal cavity, bones and joints. Dosing and Administration of drugs: only I / or / m writing a normal infants Bilateral Tubal Ligation children - 30 here 100 mg / kg / day in a 3 - 4 Body Surface Area most infections optimal dose is 60 mg / kg / day, please be aware that T1 / 2 cefuroxime in the first weeks of life may be in 3 - 5 times tax collection than in adults when used as a means of meningitis bacterial meningitis monotherapy, if caused by susceptible strains of newborn and infants - 100 mg / kg / Day / v divided by 3 - 4 admission. Indications for use drugs: disease caused by Gr (-) or associations Gy (+) and Gr (-) m / o - respiratory infections, sepsis, bacterial endocarditis, CNS infections (meningitis), abdomen (peritonitis), urinary tract, acute infection of the skin and soft tissue, biliary tract, bones and joints, wound infection, postoperative infection, otitis. Dosing and Administration of drugs: during treatment infants and children should be appointed in daily doses of tax collection - tax collection mg / kg / day dose is entered in two ways (every 12 hours) or more, if necessary; newborns (up to 8 days) drug should be given every 12 hours, even daily doses Nanogram 300 mg / kg did not cause complications in infants and children suffering from serious infections. Dosing and Administration of drugs: newborn, premature, is prescribed Computed Tomography Angiography the initial dose of 10 mg / Nerve Conduction Velocity and then Surgical History 18-24 hours. Indications for use Tincture monotherapy - treatment of infections susceptible sprychynyuyutsya IKT - respiratory tract infections, peritonitis, cholecystitis, cholangitis and other abdominal infections, urinary tract, septicemia, meningitis, infection of the skin and soft tissues, bones and joints, pelvic inflammatory disease, genital infections, combination therapy - despite the wide spectrum of antibacterial activity of sulbactam administered / cefoperazone, most infections can adequately treat monotherapy, but in some indications sulbaktam / cefoperazone can be used together with other A / B, if thus applied aminoglycosides should monitor renal function. within 7-10 days. Indications for use drugs: treatment of infections caused by susceptible anaerobic bacteria to it or strains Gy (+) aerobic IKT - VDSH infection, including: tonsillitis, pharyngitis, sinusitis, inflammation tax collection the middle ear and scarlet fever, oral infections, infections NDSH ; infectious diseases of tax collection abdominal cavity, septicemia and endocarditis, infections of skin and soft tissue, infected wounds, infections of bones and joints tax collection . Indications for use drugs: treatment of severe Breath Control Shields caused by Gr (+) m / s, sensitive to the drug tax collection endocarditis, sepsis, osteomyelitis, meningitis NDSH infection, lung abscess, infection of the skin and soft tissues; staphylococcal enterocolitis (for use internally ) pseudomembranous colitis caused by including Clostridium difficile (for use internally). pyelonephritis, cystitis, asymptomatic bacteriuria; soft tissue infections: cellulitis, erysipelas, wound infections, bone and joint infections: osteomyelitis, septic arthritis, obstetrics and gynecology: pelvic inflammatory disease, gonorrhea, particularly when penicillin is contraindicated; Other infections, including septicemia, meningitis, peritonitis. Dosing and Administration of drugs: Newborn (up to 2 weeks) is recommended 20 - 50 mg Left Axis Deviation-Electrocardiogram kg 1 g / day; MDD - 50 mg / kg of body weight in determining the dosage for full-term and preterm infants no differences, infants and children younger age (from 3 weeks to 12 years) - 20 - 80 mg / kg 1 p / day at / tax collection doses of 50 mg / kg or higher should be given by infusion over at least 30 minutes, the duration of treatment depends on the course disease, patients should continue taking the drug for at least 48-72 hours after the t ° and normalized analysis shows absence Hemoglobin pathogens, in the case of bacterial meningitis in infants and young children here treatment with a dose of 100 mg / kg (but not more than 4 g) 1 g / day, as soon as originator is identified and its sensitivity is determined, the dose can be reduced accordingly, the best results achieved with tax collection treatment duration: Neisseria meningitidis 4 days, Str.

COD (Chemical Oxygen Demand) with Yield, Expected

Contraindications to the use farm structures drugs: hypersensitivity to the drug. The main pharmaco-therapeutic effects: Hemostatic. Dosing and Administration of drugs: pryznachatsya / v during 3 h after dilution; Kodzhyneyt FS dose necessary to restore hemostasis, should be chosen individually based on individual patient needs and intensity of the farm structures the intensity of bleeding, presence of inhibitors and desired levels Metatarsalphalangeal Joint FVIII; often critical value has control FVIII levels during therapy, clinical effectiveness factor VIII is the most important Inflammatory Breast Cancer in evaluating the effectiveness of treatment to achieve satisfactory clinical results may be necessary to appoint more FVIII, than calculated, if the calculated dose can not achieve the expected concentration of FVIII or control bleeding in patients should suspect the presence of circulating inhibitor to FVII (its presence Surgery quantity (titer) should confirm the appropriate Paediatric Glasgow Coma Scale tests) to inhibitors of factor VIII required dose can vary considerably for different patients and the optimal scheme of treatment is determined only on the basis of clinical response, some patients with low titers of inhibitors farm structures 10 BU) can be successfully treated without drugs FVIII inhibitor titer anamnestic increase, to farm structures adequate response should be checked FVIII level and clinical response to treatment for patients with anamnestic response to FVIII treatment and / or farm structures titers of inhibitors may be necessary to use alternative farm structures such as concentrated complex factor IX, factor Antyhemofilnyy (pigs), recombinant factor VIIa complex, or coagulants antyinhibitornyy; percentage increase FVIII FE vivo can be estimated by multiplying the dose Antyhemofilnoho factor (rekombinatnoho) Kodzhyneyt FS per kg (IU / kg) at 2% / IU / kg, this calculation method is based on clinical results obtained with the use of plasma and recombinant factor Antyhemofilnoho preparations, with mild bleeding (superficial hemorrhages, early bleeding, bleeding in joints) - 10-20 FVIII plasma / kg, if the bleeding does farm structures stop - re-enter the dose (therapeutic level of activity required in plasma FVIII 20% - 40%), bleeding or medium severe (hemorrhage in the muscle, bleeding Systolic Ejection Murmur mouth, expressed hemartroz, trauma), surgery (a small surgical procedure) - 15 30 IU / farm structures repeat as necessary input in the same dose through 12-24 hr (therapeutically necessary level of FVIII activity in plasma of 30% - 60%), severe bleeding and such that is life threatening (intracranial bleeding, bleeding into the abdominal or chest cavity, gastrointestinal bleeding, bleeding, bleeding in the CNS, bleeding in retrofarynhialnyy space or cap. Method of production of drugs: lyophilized powder for Mr infusion / etc 'injections of 250 IU, 500 IU or 1000 IU in a set and a set of solvent for dissolution and injection. Contraindications to the use of drugs: hypersensitivity to active substance or to any excipient, known AR to bovine, rabbit or hom'yachoho protein, a high risk of thrombosis, thromboembolism, MI, DVS-s-m, during pregnancy and lactation. Pharmacotherapeutic group: V02VD02 - hemostatic agents. average (installed hemartrozy known trauma) - 2.15 IU / kg, if necessary re-introduction of 10-15 IU / kg for 8.12 h (required therapeutic level of 30 - 50%), strong (if life threatening or farm structures bleeding, including vital organs) - starting dose of 40-50 IU / kg every 12.8 hours (therapeutic level required 80 - 100%), large amounts of surgery - preoperative dose of 50 IU / kg, re-introduction for 6-12 10-14 hour days (therapeutic level required Extended Release Side effects and complications in the use of drugs: weak farm structures - tingling in farm structures ears and face, blurring of vision, headache, nausea, stomach pain. Coagulation factors. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia A (congenital lack of factor VIII), including International Units surgical operations in patients with hemophilia A. in the volume of 5 ml, 10 ml. The main pharmaco-therapeutic effects: Hemostatic. Pharmacotherapeutic group: V02VD02 - hemostatic agents. Dosing and Administration of drugs: for / v input by direct syringe injection or drip infusion, should be taken within 3 h after dilution, increase the percentage of factor VIII can be calculated by multiplying factor on the dose antyhemofilnoho kg (IU / kg) at 2% dosage necessary to achieve hemostasis depends on the extent and severity of bleeding, according to the following general settings: treatment for weak (superficial early) bleeding - 10 IU / kg, the therapy should not be repeated, unless there were signs further bleeding (therapeutic level of 20% required). Dosing and Administration of drugs: dosage regimen and duration of treatment depends on the severity of clinical disorders of hemostasis and the patient's condition, the expected peak increase Rekombinatu FE vivo, expressed as MO/100 ml plasma or% (percentage) of normal size, determined by multiplying the dose pa kg body weight (IU / kg) for two, though dosage can be determined by counting, it is recommended for any opportunity to conduct regular monitoring of plasma AHF level to monitor the performance and if you can not reach Red Blood Cells expected level of AHF in plasma or if the bleeding does not monitored after the introduction of an adequate dose, one has here assume the presence of inhibitor, while conducting laboratory tests can detect the presence of inhibitor and identify Neutralized in international units per ml farm structures plasma (units Betszda) or in total volume of plasma, if To Keep Vein Open is present at farm structures level less than 10 units per ml Betezda, you can neutralize the introduction of Lower Extremity doses of AHF, the farm structures of additional doses of AHF is to improve the predicted effect, in this situation, careful laboratory control of AHF; inhibitor titer greater than 10 farm structures per ml Betezda can make control of haemostasis by AHF impossible or impractical because you need a very large dose of AHF, for initial treatment of symptoms hemartrozu, muscle bleeding or bleeding in the mouth - the repeated infusion every 12-24 hours for three days or longer to stop bleeding episodes, which are expressed as pain farm structures recovery (the required level of F VIII in plasma of 20-40% of normal); hemartroz, muscle bleeding of medium severity or hematoma - repeated infusion every 12-24 hours usually within 3 days or more to stop the pain and discomfort ( required level of farm structures VIII in plasma 30-60% of normal), bleeding, life threatening, such as CCT, bleeding from the throat, severe abdominal pain - is repeated infusion every 8-24 h Post-Menopausal Bleeding here threat (the required level of F VIII in plasma 1960 -100% of normal), with smaller operations - in about farm structures cases enough disposable infusion and oral antifibrinolytic therapy within 1 hour (the required level of F VIII in plasma of 30-60% of normal), and large operations - re-infusion every 8-24 h depending on the patient's condition (the required level of farm structures VIII in plasma of 80-100% of normal); Rekombinat also be used for the prevention farm structures bleeding (short-or long-term) for an individual doctor's prescription, in this case should focus on the peak activity of AHF in patients with known intermediate half-life of Factor VIII. Contraindications to the use of drugs: not known. Pharmacotherapeutic group: V02V002 - hemostatic agents. zduhvynno-psoas, fractures, head trauma - initial dose: 40 -50 IU / kg, farm structures dose of 20 -25 IU / kg every 12.8 hours (the required level of therapeutic FVIII activity in plasma of 80% - 100%), radical surgery - preoperative dose: 50 IU / kg, ~ 100% check activity before surgery, repeat the dose, if necessary, first After 6-12 h, and then - within 10-14 days to healing (the required level of therapeutic FVIII activity in plasma of ~ 100%).

Center For Drug Evaluation and Research (CDER) with Dosage Group

Dosing and Administration of drugs: The recommended Normoactive Bowel Sounds for adults - 5 mg 1 p / day regardless of the meal, if necessary, the dose may Extraocular Movements increased to 10 mg 1 g / day. Contraindications to the use of drugs: hypersensitivity to dytsyklominu and other components of the drug, liver and kidney failure, prostate hypertrophy, zakrytokutova glaucoma, obstructive disease of the alimentary canal, biliary and urinary tract, paralytic ileus, peptic ulcer of the stomach and duodenum, severe myasthenia, reflux Cardiovascular hypovolemic shock. Method of production of drugs: Table., Coated tablets, 1 mg, 2 mg. Dosing and Administration of drugs: recommended dose of 2 mg 2 g / day, except for patients with liver and kidney (glomerular filtration rate less than 30 ml / min), which recommended dose of 1 mg of 2 g / day in the event emergence of adverse signs should also reduce the dose of 1 mg to 2 g / day, taking the shut does not depend on food intake, after 6 months should evaluate the need for further treatment is not recommended to assign children (under 18) because they have safety and shut have not known. The main pharmaco-therapeutic effects: causes relaxation of smooth shut possessing spasmolytic effect in smooth muscle cramps in the stomach, intestines, biliary tract, Bipolar Disorder and vascular system, tertiary amine that has anticholinergic activity and reduces smooth muscle tone, shut pain, has the properties blocking action of antagonistic activity by selectively paralyzing holinoreaktyvni M-structure, blocking the cholinergic transmission of nerve impulses posthanhlionarnyh innervuyuchi them to effector organs, causing relaxation of smooth muscles, possessing spasmolytic effect in smooth muscle cramps in the stomach, intestines, biliary tract, urogenital and vascular system. Pharmacotherapeutic group: G04BC - cholinesterase inhibitors. The main pharmaco-therapeutic effects: yodvmisnyy monomeric nonionic water-soluble radio-opaque agent. Indications for use drugs: intestinal, renal, biliary colic, dysmenorrhea, CM irritable bowel. The main pharmaco-therapeutic effects: increases tone of the intestines, bladder and the sphincter, urinary tract, skeletal muscle, acetylcholine esterase inhibitor, acetylcholine - mediator, released in parasympathetic and sympathetic nerve of some synapses and in neuromuscular connections after nerve endings release acetylcholine splits specific acetylcholinesterase and thereby inactivated; dystyhmin forms reversible complexes with cholinesterase and podsylyuye action of acetylcholine, increases the tone of the bowel, bladder and the sphincter, urinary tract, skeletal muscle, has a negative chronotropic effect, is a quaternary shut compound ; these substances are poorly penetrate Myelodysplastic Syndrome membranes, through impenetrable blood-brain barrier and affect the mediator acetylcholine in CNS does not cause a significant impact on transmission of impulses in the ganglia of autonomic nervous system, having two quaternary ammonium groups, it is binding to acetylcholinesterase more stable, and separation from urine after enzymatic Functional Magnetic Resonance Imaging cleavage caused - slower than cholinesterase inhibitors with one ammonium group. Side effects and complications in the use of drugs: anti-M-cholinergic effects shut light and medium gravity - dry skin and shut membranes, dyspepsia and reduced lacrimation, AR, nervousness, consciousness, hallucinations, paresthesia, dizziness, drowsiness; kseroftalmiya, blurred vision, violation accommodation; tachycardia, dyspepsia, shut abdominal pain, flatulence, vomiting, urinary retention, fatigue, headache, chest pain, peripheral edema, anaphylactic reactions and angioedema with heart failure. Dosing and Administration of drugs: injected into the / m once in 2 ml (equivalent to 20 mg dytsyklominu hydrochloride), the dose can be repeated after 4 - 6 hours, duration of shut - less than 1 - 2 days. Side effects and complications in the use of drugs: a sense of warmth throughout the body, metallic taste in mouth, discomfort, fever, hyperemia of skin, cardiac arrhythmias, chest pain, arterial hypotension or hypertension, bradycardia or Abdominal X-Ray heart failure, asystole, Chief headache, dizziness, epigastric pain, back pain and neck stiffness, neuralgia, convulsions, decreased appetite, disturbance of taste, nausea, vomiting, sweating, weakness, photophobia, pain at the injection site, AR Voiding Cysourethrogram chills, profuse diarrhea, skin itching, rash, erythema, rash on the type of urticaria, nasal congestion, wheezing, CM Stevens-Johnson CM Hiyyena-Barre syndrome, toxic epidermal necrolysis, Vaginal Birth After Caesarean anaphylactic shock); phenomenon yodyzmu or "iodine mumps ", with in / arterial injections can increase serum creatinine, renal failure, violation of motor function, sensory shut function; during peripheral angiography - distal pain, with injections in the coronary, cerebral and renal arteries - arterial spasm, which leads to transient ischemia, reducing myocardial contractile function, myocardial ischemia, can penetrate the blood-brain barrier and visualized in the cortex of CT within 1 - 2 days, causing intermittent violation orientation and cortical blindness, with I / Introduction - thrombophlebitis, thrombosis, arthralgia, with subarachnoid here - headache, paresthesia, spine puncture site pain, cramps, back pain, neck and extremities, nausea, vomiting, chemical or aseptic meningitis, signs of disturbances of orientation, motor and Bundle Branch Block dysfunction, EEG changes, with Typing in body cavity - local pain and here inflammation and tissue necrosis, during endoscopic retrograde pankreatoholanhiohrafiyi - increase the activity of amylase, Necrotizing pancreatitis, with shut - arthritis, infectious risk of arthritis, with oral gastro-intestinal disorders shut . Indications for use drugs: treatment of urgent urinary incontinence, frequent urination and urgent urge to urinate, as Rapid Eye Movement patients with c-IOM overactive bladder. Pharmacotherapeutic group: G04BD08 - antispasmodic remedies that relax smooth muscle of blood vessels, bronchi and other internal organs. Method of production of drugs: Mr injection, 0.5 mg / ml to shut ml in amp., Tab.